Mandate

Vinge advised Orexo on its divestment of Kibion

May 05, 2015

Orexo AB (publ) (Nasdaq Stockholm) has divested its subsidiary Kibion to a group of investors. Vinge advised Orexo.

The Vinge team included Erik Sjöman (partner, capital markets and M&A) and associates Christian Lindhé, Kristoffer Franzkeit and Cecilia Cronqvist.

Related

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026

Vinge has advised Skeptiva AB in connection with its financing round

Skeptiva is developing the next generation of cybersecurity defenses against fraud. The company has developed an AI application that detects attacks and alerts users in real time.
March 11, 2026

Vinge has advised Main Capital in connection with the acquisition of Good Solutions Sweden AB

Good Solutions Sweden AB (”Good Solutions”) provides software that helps factories identify and reduce production losses. The software converts data from machines and operators into insights that can be used to streamline production and increase profitability.
March 11, 2026